{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:43:45Z","timestamp":1761896625571,"version":"3.37.3"},"reference-count":26,"publisher":"Informa UK Limited","issue":"10","funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2017,10,3]]},"DOI":"10.1080\/17474086.2017.1369399","type":"journal-article","created":{"date-parts":[[2017,9,8]],"date-time":"2017-09-08T13:48:21Z","timestamp":1504878501000},"page":"933-939","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent"],"prefix":"10.1080","volume":"10","author":[{"given":"Paul","family":"Richardson","sequence":"first","affiliation":[{"name":"Department of Hematologic Oncology, Dana Farber Cancer Institute, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuja","family":"Roy","sequence":"additional","affiliation":[{"name":"Department of Global Value & Access, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suddhasatta","family":"Acharyya","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok","family":"Panneerselvam","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estella","family":"Mendelson","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"G\u00fcnther","sequence":"additional","affiliation":[{"name":"Division of Stem Cell Transplantation and Immunotherapy, 2nd Department of Medicine, University Hospital Schleswig-Holstein and University of Kiel, Kiel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik II, Julius Maximilians Universitaet, Wuerzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2017,9,25]]},"reference":[{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2010.00725.x"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28340"},{"key":"CIT0004","first-page":"Doc10","volume":"5","author":"Muhlbacher AC","year":"2008","journal-title":"Psychosoc Med"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1548-y"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.09.011"},{"journal-title":"Pharmacol Res","year":"2016","author":"Richardson PG","key":"CIT0010"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.15.1039"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70440-1"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt297"},{"key":"CIT0014","unstructured":"NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae). Multiple Myeloma. Version 2. 2017 \u2013 [2016 Oct 28]."},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-275800"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.147"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-517276"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-425934"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-556308"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321"},{"volume-title":"Pomalyst [prescribing information]","year":"2015","key":"CIT0022"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01120-4"},{"volume-title":"Empliciti (elotuzumab) [prescribing information]","year":"2015","key":"CIT0024"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2518"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S38142"},{"issue":"4","key":"CIT0028","first-page":"204","volume":"8","author":"Roy A","year":"2015","journal-title":"Am Health Drug Ben"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.120121"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30147-8"},{"issue":"7","key":"CIT0031","doi-asserted-by":"crossref","first-page":"19","DOI":"10.18553\/jmcp.2008.14.S7-A.19","volume":"14","author":"Cook R","year":"2008","journal-title":"J Manag Care Pharm"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.185"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2017.1369399","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T14:04:49Z","timestamp":1659449089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2017.1369399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,25]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,8,21]]},"published-print":{"date-parts":[[2017,10,3]]}},"alternative-id":["10.1080\/17474086.2017.1369399"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2017.1369399","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"type":"print","value":"1747-4086"},{"type":"electronic","value":"1747-4094"}],"subject":[],"published":{"date-parts":[[2017,9,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"}]}}